Drug Price Trends for TRIAMTERENE-HYDROCHLOROTHIAZIDE

Average Pharmacy Cost for TRIAMTERENE-HYDROCHLOROTHIAZIDE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	72578-0090-10	0.10807	EACH	2025-02-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	00781-2074-10	0.10807	EACH	2025-02-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	72578-0090-01	0.10807	EACH	2025-02-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	00527-1632-01	0.10807	EACH	2025-02-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.10807	EACH	2025-02-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	00527-1632-10	0.10807	EACH	2025-02-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	00781-2074-01	0.10807	EACH	2025-02-19

Market Analysis and Price Projections for Triamterene-Hydrochlorothiazide

Introduction

Triamterene-hydrochlorothiazide is a combination medication that belongs to the class of potassium-sparing diuretics with thiazides. It is commonly used to treat conditions such as hypertension and edema. Here, we will delve into the market analysis and price projections for this drug, highlighting key factors, trends, and future outlook.

Market Drivers and Trends

The demand for triamterene-hydrochlorothiazide is driven by several key factors:

• Increasing Prevalence of Hypertension: Approximately 47% of adults aged 30 and older are diagnosed with hypertension, a condition exacerbated by lifestyle factors such as poor dietary habits, sedentary behavior, and heightened stress levels. This growing incidence underscores the need for effective antihypertensive treatments like triamterene-hydrochlorothiazide[4].
• Aging Population: The global aging population is another significant driver, as older adults are more likely to suffer from hypertension and related cardiovascular disorders[4].
• Therapeutic Efficacy: The combination of triamterene and hydrochlorothiazide enhances diuretic efficacy by counteracting the potassium loss associated with hydrochlorothiazide, making it a preferred treatment option for managing blood pressure[4].

Market Size and Growth

The global diuretic drugs market, which includes triamterene-hydrochlorothiazide, is expected to grow significantly. Here are some key statistics:

• Current Market Size: The diuretic drugs market was valued at approximately USD 99.8 million in 2022[3].
• Forecasted Growth: The market is projected to reach USD 165.1 million by 2032, growing at a CAGR of 5.3% from 2023 to 2032[3].

Segmentation and Regional Analysis

The market can be segmented based on several criteria:

• By Drug Class: Potassium-sparing diuretics, which include triamterene-hydrochlorothiazide, are a significant segment within the diuretic drugs market[3].
• By Indication: Hypertension and edema are the primary indications driving the demand for this medication[3].
• By Region: The global market is diverse, with significant demand coming from regions with high prevalence rates of hypertension, such as North America and Europe[1].

Price Analysis and Projections

The prices of triamterene-hydrochlorothiazide vary based on the dosage form, quantity, and pharmacy:

• Oral Tablets: The cost for hydrochlorothiazide/triamterene (25 mg-37.5 mg) oral tablets is around $11 for a supply of 15 tablets. For higher strengths like 50 mg-75 mg, the price starts at approximately $13.84 for 15 tablets[2].
• Oral Capsules: The cost for hydrochlorothiazide/triamterene oral capsules starts at around $20.28 for 90 capsules[2].

Factors Influencing Pricing

Several factors influence the pricing of triamterene-hydrochlorothiazide:

• Raw Material Costs: The costs of essential raw materials such as triamterene and hydrochlorothiazide significantly impact the final product price[4].
• Manufacturing Expenses: Increases in utility costs and other manufacturing expenses can drive up the price of the medication[4].
• Market Demand: Fluctuations in market demand can also affect pricing, with higher demand potentially leading to higher prices[4].
• Regulatory Changes: Changes in regulatory policies can influence the pricing strategy of manufacturers[4].

Competitive Landscape

The market for triamterene-hydrochlorothiazide is competitive, with several key players:

• Teva Pharmaceuticals: Recently launched a generic version of triamterene and hydrochlorothiazide tablets, offering a more affordable alternative to brand-name medications[4].
• Aurobindo Pharma: Another major player in the market, known for its generic and branded pharmaceutical products[4].
• Sandoz: A leading manufacturer of generic and biosimilar medicines, including diuretic drugs[4].

Challenges and Opportunities

Despite the growing demand, the market faces several challenges:

• Supply Chain Risks: Disruptions in raw material availability and increasing utility costs can threaten supply stability[4].
• Regulatory Compliance: Manufacturers must comply with stringent regulatory requirements, which can be both a challenge and an opportunity for differentiation[4].

Future Outlook

The future outlook for triamterene-hydrochlorothiazide is promising due to the increasing prevalence of hypertension and the growing need for effective antihypertensive treatments. Here are some key points:

• Growing Demand: The demand for triamterene-hydrochlorothiazide is expected to continue growing, driven by the rising incidence of hypertension and related disorders[4].
• Technological Innovations: Advancements in drug formulations and manufacturing processes could lead to more efficient and cost-effective production, potentially reducing prices and increasing accessibility[4].
• Market Expansion: The market is expected to expand into new regions, particularly in areas with high prevalence rates of hypertension, offering new opportunities for growth[1].

Key Takeaways

• The demand for triamterene-hydrochlorothiazide is driven by the increasing prevalence of hypertension and the growing aging population.
• The global diuretic drugs market is expected to grow at a CAGR of 5.3% from 2023 to 2032.
• Pricing is influenced by raw material costs, manufacturing expenses, market demand, and regulatory changes.
• The market is competitive, with key players like Teva Pharmaceuticals, Aurobindo Pharma, and Sandoz.
• Despite challenges, the future outlook is promising due to growing demand and technological innovations.

FAQs

Q: What are the primary indications for triamterene-hydrochlorothiazide? A: The primary indications for triamterene-hydrochlorothiazide are hypertension and edema[2].

Q: How does the combination of triamterene and hydrochlorothiazide work? A: The combination enhances diuretic efficacy by counteracting the potassium loss associated with hydrochlorothiazide, making it a preferred treatment option for managing blood pressure[4].

Q: What is the expected growth rate of the diuretic drugs market? A: The diuretic drugs market is expected to grow at a CAGR of 5.3% from 2023 to 2032[3].

Q: Which regions are expected to dominate the market for triamterene-hydrochlorothiazide? A: Regions with high prevalence rates of hypertension, such as North America and Europe, are expected to dominate the market[1].

Q: What are the key factors influencing the pricing of triamterene-hydrochlorothiazide? A: The key factors include raw material costs, manufacturing expenses, market demand, and regulatory changes[4].

Cited Sources

1. Cognitivemarketresearch.com - Global Triamterene Hydrochlorothiazide Market Report 2024 Edition
2. Drugs.com - Hydrochlorothiazide/triamterene Prices, Coupons, Copay Cards & Patient Assistance
3. Marketresearch.biz - Diuretic Drugs Market Size, Share Trends, Analysis, Forecast 2032
4. Expertmarketresearch.com - Triamterene Hydrochlorothiazide Manufacturing Plant Project Report
5. Drugs.com - Triamterene Prices, Coupons, Copay Cards & Patient Assistance